

Retail Equity Research

Dabur India Limited

FMCG

BSE CODE: 500096 Bloomberg CODE: DABUR:IN

KEY CHANGES:

NSE CODE: DABUR SENSEX: 49,581

BUY

EARNINGS

12M Investment period Rating as per Large Cap

CMP Rs. 534

RATING (

TARGET Rs. 612 RETURN 15% (Closing: 17-05-21)

All-round performance in Q4; Outlook positive

Dabur India Ltd (Dabur), a leading Indian FMCG company, is a world leader in Ayurveda with a portfolio of over 250 Herbal/Ayurvedic products. The company operates through Health Supplements, Digestives, Shampoos, Hair Oils, Skin Care, Oral Care, Foods and Other OTC & Ethical products.

TARGET 1

- Q4FY21 sales grew 25.3% YoY, on strong demand-driven growth in Healthcare, Home & Personal Care and Food & Beverage businesses.
- Despite stable EBITDA margin of 18.9%, EBITDA rose 25.6% YoY on robust topline growth. Resultantly, PAT also grew 25.5% YoY.
- Amidst the second wave of pandemic, the company has taken adequate precautions in terms of inventory management and is well placed to tackle any potential supply chain disruptions. We expect company's growth momentum to continue aided by robust demand, and hence reiterate our BUY rating on the stock with a revised TP of Rs. 612 based on 50x FY23E adj. EPS.

Strong product traction aids topline growth

Q4FY21 revenue surged 25.3% YoY to Rs. 2,337cr, led by strong growth in both domestic (+30.3% YoY) and International businesses (+19.4% YoY). In domestic healthcare segment, OTC rose 34.0% YoY led by growth in Lal Tail and Shilajit. Digestives revenue went up 20.0% YoY aided by growth in Pudin Hara, while Health supplements grew 17.7% YoY due to higher sales of Chyawanprash and honey. Ethicals revenue increased 39.1% YoY on distribution expansion, and innovations. Under Home and Personal Care, oral care grew 42.1% YoY with strong demand in red toothpaste, Meswak, and Babool. Shampoo and Hair oils witnessed strong growth of 33.4% and 24.6% YoY, respectively. Home Care revenue rose 24.3% YoY on growth in Odonil and Odomos. Under F&B, Beverages grew 27.1% YoY on strong traction in juices, nectar and still drinks. Foods rose 36.1% YoY supported by Hommade brand, chutneys, and pickles. International business reported constant currency growth in Bangladesh (+46.7% YoY), MENA (+24.1%), SSA (+22.0%) and Egypt (+21.9%).

Robust sales supports profitability

While EBITDA margin remained stable YoY at 18.9%, overall EBITDA rose 25.6% YoY to Rs. 442cr, primarily driven by higher sales, partially offset by higher input prices, and employee and other expenses. As a result, Adj. PAT also increased 25.5% YoY to Rs. 378cr, due to higher operating profit and other income.


Key concall highlights

- Focusing on innovation in consumer products, Dabur recently launched Vatika Select shampoo with ingredients like Moroccan argan and red onion seeds.
- Company plans to invest around Rs. 550cr over the next 4-5 years on its new Greenfield facility in Central India for its healthcare business.
- Management guided double digit value growth for FY22 on the back of expected high single digit growth in volumes and a price increase of \sim 3%.

Valuation

Company is prepared for extended lockdown by keeping high levels of inventory to support traction in newly launched products. Healthcare products are set to witness strong performance over medium term, as customers focus on immunity booster and healthy lifestyle. Rural segment is less likely to be impacted from lockdown with support from government stimulus. We expect company's growth momentum to continue aided by robust demand and hence reiterate our BUY rating on the stock with a revised target price of Rs. 612 based on 50x FY23E adj. EPS.

Company Data						
Market Cap (cr)			Rs. 92,670			
Enterprise Value (cr)	Rs. 91,638					
Outstanding Shares (cr)		177.3			
Free Float			32.0%			
Dividend Yield			0.9%			
52 week high			Rs. 581			
52 week low			Rs. 421			
6m average volume (lac)		2.3			
Beta			0.5			
Face value			Rs. 1			
Shareholding %	Q2FY21	Q3FY21	Q4FY21			
Promoters	67.9	67.9	67.4			
FII's	18.1	18.5	19.8			
MFs/Insti	6.9	5.9	5.3			
Public	5.5	5.6	5.5			
Others	1.7	2.1	2.0			
Total	100.0	100.0	100.0			
Promoters' pledge	0.0	0.0	0.0			
Price Performance	3 Month	6 Month	1 Year			
Absolute Return	-0.4%	1.5%	17.0%			
Absolute Sensex	-3.5%	14.4%	56.4%			
Relative Return*	3.2%	-12.9%	-39.4%			
*over or under performance to benchmark index						



Consolidated (cr)	FY21A	FY22E	FY23E
Sales	9,562	10,752	11,957
Growth (%)	9.9	12.5	11.2
EBITDA	2,003	2,294	2,608
EBITDA Margin (%)	20.9	21.3	21.8
Adj. PAT	1,693	1,903	2,172
Growth (%)	9.6	12.4	14.1
Adj. EPS	9.6	10.7	12.2
Growth (%)	9.6	12.4	14.1
P/E	56.6	48.7	42.7
P/B	12.5	11.0	9.9
EV/EBITDA	47.5	39.9	35.0
ROE (%)	22.1	22.5	23.1
D/E	0.1	0.1	0.1





Quarterly Financials (Consolidated)

Profit & Loss Account

	Q4FY21	Q4FY20	YoY Growth %	Q3FY21	QoQ Growth %	FY21	FY20	YoY Growth %
Revenue	2,337	1,865	25.3	2,729	(14.4)	9,562	8,704	9.9
EBITDA	442	352	25.6	574	(22.9)	2,003	1,792	11.7
EBITDA margins	18.9	18.9	-	21.0	(210bps)	20.9	20.6	30bps
Depreciation	67	59	13.2	57	16.5	240	220	8.9
EBIT	376	293	28.1	517	(27.3)	1,763	1,572	12.1
Interest	9	9	0.8	7	25.8	31	50	(37.8)
Other Income	85	76	12.2	81	5.0	325	305	6.6
Exceptional Items	-	(20)	n.m.	-	n.m.	-	(100)	n.m.
PBT	452	340	32.7	591	(23.6)	2,056	1,728	19.0
Tax	74	59	26.8	97	(23.7)	361	280	29.1
Sh. of profit from Associate	(1)	(0)	n.m.	(0)	n.m.	(1)	(0)	n.m.
Minority Interest	(1)	0	n.m.	1	n.m.	2	3	(44.3)
Reported PAT	378	281	34.4	492	(23.2)	1,693	1,445	17.2
Adjustments	-	20	n.m.	-	n.m.	-	100	n.m.
Adj. PAT	378	301	25.5	492	(23.2)	1,693	1,545	9.6
No. of shares	177.4	176.8	0.3	177.0	0.2	177.4	176.8	0.3
Adj. EPS (Rs.)	2.1	1.7	25.1	2.8	(23.4)	9.6	8.7	9.3

Change in Estimates

	Old est	imates	New est	timates	Chai	nge %
Year / Rs. cr	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
Revenue	10,426	-	10,752	11,957	3.1	-
EBITDA	2,310	-	2,294	2,608	(0.7)	-
Margins (%)	22.2	-	21.3	21.8	(90bps)	-
Adj. PAT	1,948	-	1,903	2,172	(2.3)	-
Adj. EPS	11.0	-	10.7	12.2	(2.6)	-



PROFIT & LOSS

Y.E March (Rs. cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Revenue	8,533	8,704	9,562	10,752	11,957
% change	10.1	2.0	9.9	12.5	11.2
EBITDA	1,740	1,792	2,003	2,294	2,608
% change	7.6	3.0	11.7	14.5	13.7
Depreciation	177	220	240	250	256
EBIT	1,563	1,572	1,763	2,044	2,372
Interest	60	50	31	42	59
Other Income	222	205	324	331	347
PBT	1,725	1,728	2,056	2,332	2,661
% change	1.9	0.2	19.0	13.4	14.1
Tax	279	280	361	427	487
Tax Rate (%)	16.2	16.2	17.6	18.3	18.3
Reported PAT	1,442	1,445	1,693	1,903	2,172
Adj*	75	100	-	-	-
Adj PAT	1,518	1,545	1,693	1,903	2,172
% change	10.9	1.8	9.6	12.4	14.1
No. of shares (cr)	177.2	177.3	177.3	177.3	177.3
Adj EPS (Rs.)	8.6	8.7	9.6	10.7	12.2
% change	10.6	1.7	9.6	12.4	14.1
DPS (Rs.)	2.8	1.6	4.8	5.0	5.8
CEPS (Rs.)	9.6	10.0	10.9	12.1	13.7

BALANCE SHEET

Y.E March (Rs. cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Cash	328	811	1,329	1,556	1,901
Accounts Receivable	834	814	562	645	777
Inventories	1,301	1,380	1,734	1,851	2,200
Other Cur. Assets	1,124	1,875	1,151	1,151	1,151
Investments	2,685	1,461	3,464	3,964	4,464
Gross Fixed Assets	2,226	2,627	2,933	3,229	3,516
Net Fixed Assets	1,548	1,821	1,812	1,850	1,873
CWIP	64	147	147	155	162
Intangible Assets	369	380	381	387	394
Def. Tax (Net)	1	23	22	22	22
Other Assets	183	642	245	252	259
Total Assets	8,437	9,354	10,847	11,833	13,204
Current Liabilities	2,162	2,160	2,585	2,764	3,186
Provisions	60	63	63	73	84
Debt Funds	529	472	485	485	485
Other Liabilities	23	17	14	15	16
Equity Capital	177	177	177	177	177
Reserves & Surplus	5,455	6,429	7,487	8,281	9,216
Shareholder's Fund	5,632	6,606	7,664	8,458	9,393
Minority Interest	31	36	37	39	41
Total Liabilities	8,437	9,354	10,847	11,833	13,204
BVPS (Rs.)	32	37	43	48	53

CASH FLOW

Y.E March (Rs. cr)	FY19A	FY20A	FY21A	FY22E	FY23E
Net inc. + Depn.	1,619	1,665	1,933	2,154	2,428
Non-cash adj.	9	(13)	(146)	(459)	(441)
Changes in W.C	(129)	(39)	327	(22)	(59)
C.F. Operation	1,499	1,614	2,115	1,674	1,928
Capital exp.	(225)	(400)	(306)	(296)	(287)
Change in inv.	317	(365)	(1,361)	(500)	(500)
Other invest.CF	244	248	262	275	288
C.F - Investment	337	(517)	(1,406)	(521)	(499)
Issue of equity	0	0	0	-	-
Issue/repay debt	(240)	(397)	(2)	-	-
Dividends paid	(1,597)	(618)	(592)	(884)	(1,025)
Other finance.CF	(52)	(28)	(19)	(42)	(59)
C.F - Finance	(1,888)	(1,043)	(613)	(926)	(1,084)
Chg. in cash	(52)	54	95	227	345
Closing cash	328	811	1,329	1,556	1,901

RATIOS

Y.E March	FY19A	FY20A	FY21A	FY22E	FY23E
Profitab. & Return					
EBITDA margin (%)	20.4	20.6	20.9	21.3	21.8
EBIT margin (%)	18.3	18.1	18.4	19.0	19.8
Net profit mgn. (%)	16.9	16.6	17.7	17.7	18.2
ROE (%)	25.6	21.9	22.1	22.5	23.1
ROCE (%)	25.2	22.1	21.5	22.8	23.9
W.C & Liquidity					
Receivables (days)	35.7	34.1	21.4	21.9	23.7
Inventory (days)	110.2	115.5	132.2	124.1	125.9
Payables (days)	123.3	124.1	146.0	140.4	144.0
Current ratio (x)	1.3	2.0	1.6	1.7	1.7
Quick ratio (x)	0.7	1.2	0.9	0.9	1.0
Turnover & Leverage					
Gross asset T.O (x)	3.9	3.6	3.4	3.5	3.5
Total asset T.O (x)	1.0	1.0	0.9	0.9	1.0
Int. coverage ratio (x)	26.2	31.7	57.2	48.4	40.3
Adj. debt/equity (x)	0.1	0.1	0.1	0.1	0.1
Valuation					
EV/Sales (x)	8.5	9.1	9.9	8.5	7.6
EV/EBITDA (x)	41.8	44.4	47.5	39.9	35.0
P/E (x)	47.7	51.7	56.6	48.7	42.7
P/BV (x)	12.9	12.1	12.5	11.0	9.9





Recommendation Summary



Dates	Rating	Target
16-May-18	BUY	409
24-Jul-19	BUY	464
19-Nov-19	HOLD	499
04-Feb-20	HOLD	527
04-Aug-20	HOLD	537
09-Nov-20	BUY	584
18-May-21	BUY	612

Investment Rating Criteria

Ratings	Large caps	Midcaps	Small Caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10%-15%	Upside is between 10%-20%
Hold	Upside is between 0% - 10%	Upside is between 0%-10%	Upside is between 0%-10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%
Not rated			

Definition:

Buy: Acquire at Current Market Price (CMP), with the target mentioned in the research note.

Accumulate: Partial buying or to accumulate as CMP dips in the future.

Hold: Hold the stock with the expected target mentioned in the note.

Reduce: Reduce your exposure to the stock due to limited upside. The stock may still be a quality stock.

Sell: Exit from the stock.

Not rated: The analyst has no investment opinion on the stock.

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/ return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

General Disclosures and Disclaimers

CERTIFICATION

I, Vincent K A, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Financial Services Limited, hereinafter referred to as Geojit.

COMPANY OVERVIEW

Geojit, a publically listed company, is engaged in services of retail broking, depository services, portfolio management and marketing investment products including mutual funds, insurance and properties. GEOJIT is a SEBI registered Research Entity and as such prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India Act, 1992, Securities And Exchange Board Of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

DISTRIBUTION OF REPORTS: This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. GEOJIT will not treat the recipients of this report as clients by virtue of their receiving this report.

GENERAL REPRESENTATION: The research reports do not constitute an offer or solicitation for the purchase or sale of any financial instruments, inducements, promise, guarantee, warranty, or as an official confirmation of any transaction or contractual obligations of any kind. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. We have also reviewed the research report for any untrue statements of material facts or any false or misleading information. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

RISK DISCLOSURE: GEOJIT and/or its Affiliates and its officers, directors and employees including the analyst/authors shall not be in any way be responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Investors may lose his/her entire investment under certain market conditions so before acting on any advice or recommendation in these material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. This report does not take into account the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The user assumes





the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved). The price, volume and income of the investments referred to in this report may fluctuate and investors may realize losses that may exceed their original capital.

FUNDAMENTAL DISCLAIMER: We have prepared this report based on information believed to be reliable. The recommendations herein are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. This report is non-inclusive and does not consider all the information that the recipients may consider material to investments. This report is issued by GEOJIT without any liability/undertaking/commitment on the part of itself or any of its entities. We may have issued or may issue on the companies covered herein, reports, recommendations or information which is contrary to those contained in this report. The projections and forecasts described in this report should be evaluated keeping in mind the fact that these are based on estimates and assumptions and will vary from actual results over a period of time. The actual performance of the companies represented in the report may vary from those projected. These are not scientifically proven to guarantee certain intended results and hence, are not published as a warranty and do not carry any evidentiary value whatsoever. These are not to be relied on in or as contractual, legal or tax advice. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

CRISIL has provided research support in preparation of this research report and the investment rational contained herein along with financial forecast. The target price and recommendation provided in the report are strictly Geojit's views and are NOT PROVIDED by CRISIL. Further, CRISIL expresses no opinion on valuation and the associated recommendations. CRISIL has no financial liability whatsoever, to the subscribers / users of this report.

JURISDICTION: The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

REGULATORY DISCLOSURES: GEOJIT's Associates consists of privately held companies such as Geojit Technologies Private Limited (GTPL- Software Solutions provider), Geojit Credits Private Limited (GCPL- NBFC Services provider), Geojit Investment Services Limited (GISL- Corporate Agent for Insurance products), Geojit Financial Management Services Private Limited (GFMSL) & Geojit Financial Distribution Private Limited (GFDPL), (Distributors of Insurance and MF Units). In the context of the SEBI Regulations on Research Analysts (2014), GEOJIT affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports /research analysis etc that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities. In compliance with the above mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment decision:

1. Disclosures regarding Ownership*:

GEOJIT confirms that:

It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein.

It/its associates have no actual beneficial ownership greater than 1% in relation to the subject company (ies) covered herein.

Further, the Analyst confirms that:

He, his associates and his relatives have no financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company.

He, his associates and his relatives have no actual/beneficial ownership greater than 1% in the subject company covered

2. Disclosures regarding Compensation:

During the past 12 months, GEOJIT or its Associates:

- (a) Have not received any compensation from the subject company; (b) Have not managed or co-managed public offering of securities for the subject company (c) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company (d) Have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company and is in receipt of compensation from the subject company." (e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report (f) The subject company is / was not a client during twelve months preceding the date of distribution of the research report.
- 3. Disclosure by GEOJIT regarding the compensation paid to its Research Analyst:

GEOJIT hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to trading in securities of companies contained in the Research Reports.

4. Disclosure regarding the Research Analyst's connection with the subject company:

It is affirmed that I, Vincent K A, Research Analyst(s) of GEOJIT have not served as an officer, director or employee of the subject company

5. Disclosure regarding Market Making activity:

Neither GEOJIT/its Analysts have engaged in market making activities for the subject company.

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange Board of India before investing.

Geojit Financial Services Ltd. (formerly known as Geojit BNP Paribas Financial Services Ltd.), Registered Office: 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website: www.geojit.com. For investor queries: customercare@geojit.com, For grievances: grievances@geojit.com, For compliance officer: compliance@geojit.com.

Corporate Identity Number: L67120KL1994PLC008403, SEBI Stock Broker Registration No INZ000104737, Research Entity SEBI Reg No: INH200000345, Investment Adviser SEBI Reg No: INA200002817, Portfolio Manager: INP000003203, Depository Participant: IN-DP-325-2017, ARN Regn.Nos:0098, IRDA Corporate Agent (Composite) No.: CA0226

